Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report)'s stock price was down 5.1% on Thursday . The company traded as low as $4.62 and last traded at $4.66. Approximately 22,462,030 shares changed hands during trading, an increase of 61% from the average daily volume of 13,988,351 shares. The stock had previously closed at $4.91.
Analysts Set New Price Targets
A number of equities research analysts have recently weighed in on RXRX shares. Morgan Stanley dropped their price objective on Recursion Pharmaceuticals from $10.00 to $8.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. Cowen reaffirmed a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Needham & Company LLC dropped their price objective on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Finally, Leerink Partners dropped their price objective on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average price target of $7.60.
Get Our Latest Report on Recursion Pharmaceuticals
Recursion Pharmaceuticals Price Performance
The stock has a market capitalization of $2.23 billion, a price-to-earnings ratio of -3.59 and a beta of 0.84. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.35 and a current ratio of 4.35. The company has a 50 day moving average of $4.81 and a 200 day moving average of $6.35.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The company had revenue of $14.75 million for the quarter, compared to analyst estimates of $18.12 million. During the same period in the previous year, the firm earned ($0.39) earnings per share. The company's revenue for the quarter was up 7.2% compared to the same quarter last year. As a group, equities research analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current year.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently bought and sold shares of the stock. Private Trust Co. NA acquired a new position in Recursion Pharmaceuticals during the 4th quarter worth $27,000. AlphaQuest LLC acquired a new position in Recursion Pharmaceuticals during the 1st quarter worth $36,000. GAMMA Investing LLC grew its stake in Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock worth $38,000 after purchasing an additional 2,026 shares in the last quarter. Farther Finance Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock worth $52,000 after acquiring an additional 1,353 shares in the last quarter. Finally, NewEdge Advisors LLC boosted its position in shares of Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock worth $53,000 after acquiring an additional 2,387 shares in the last quarter. 89.06% of the stock is owned by institutional investors and hedge funds.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Further Reading
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
